Published in Infect Dis Rep on March 30, 2017
Development of an antibiotic marker-free platform for heterologous protein production in Streptomyces. Microb Cell Fact (2017) 0.75
Antibiotic resistance-the need for global solutions. Lancet Infect Dis (2013) 15.01
Challenges of antibacterial discovery. Clin Microbiol Rev (2011) 3.94
Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ (2016) 2.01
Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. Lancet Infect Dis (2015) 1.75
Understanding the mechanisms and drivers of antimicrobial resistance. Lancet (2015) 1.52
The cost of drug development: a systematic review. Health Policy (2011) 1.37
Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect Dis (2016) 1.27
Medicare and Medicaid Programs; Reform of Requirements for Long-Term Care Facilities. Final rule. Fed Regist (2016) 1.19
Antibiotic effectiveness: balancing conservation against innovation. Science (2014) 1.12
Control of fluoroquinolone resistance through successful regulation, Australia. Emerg Infect Dis (2012) 1.11
Antibiotic research and development: business as usual? J Antimicrob Chemother (2015) 0.99
The negative impact of antibiotic resistance. Clin Microbiol Infect (2015) 0.90
Closing the divide: the Harvard Global Equity Initiative-Lancet Commission on global access to pain control and palliative care. Lancet (2015) 0.90
Antibiotics in Wastewater of a Rural and an Urban Hospital before and after Wastewater Treatment, and the Relationship with Antibiotic Use-A One Year Study from Vietnam. Int J Environ Res Public Health (2016) 0.83
Accelerating global innovation to address antibacterial resistance: introducing CARB-X. Nat Rev Drug Discov (2016) 0.80
Australian Group on Antimicrobial Resistance Community-onset Gram-negative Surveillance Program annual report, 2010. Commun Dis Intell Q Rep (2013) 0.78
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis (2014) 2.65
Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet (2006) 2.32
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis (2014) 1.80
Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother (2014) 1.19
International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet (2015) 1.05
An assessment of the future impact of alternative technologies on antibiotics markets. J Pharm Policy Pract (2016) 0.75
Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. Int J Antimicrob Agents (2016) 0.75
Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance. Clin Infect Dis (2017) 0.75